

FireGate Biotech

Lux Veritas™ — Oversight-Driven Biotechnology

Investor Package 2025

Preface

This package is provided under FireGate Biotech's commitment to open science and transparency. Data are derived from published studies and structured into pooled analyses by FireGate's oversight architecture. Our goal is to accelerate discovery while ensuring scientific integrity and accountability.

FireGate Biotech — Innovation inseparable from accountability

Abstract

Background: CCR5 antagonists have been studied in HIV treatment across multiple trials. We conducted a guided meta-analysis to evaluate pooled effects. Methods: Systematic review of 12 studies (n=1,248) assessing viral load reduction and CD4+ T-cell counts. Pooled effect sizes calculated using random-effects models. Forest plots and PRISMA diagram illustrate findings. Results: CCR5 blockade produced a mean viral load reduction of $-1.82 \log_{10}$ copies/mL (95% CI: -1.65 to -1.98) and an increase in CD4+ T-cells of $+143$ cells/ μ L (95% CI: $+120$ to $+166$). Moderate heterogeneity observed ($I^2=32\%$). No major safety concerns identified. Conclusions: CCR5 antagonists demonstrate consistent virologic and immunologic benefit, supporting their integration into curative HIV strategies with immune checkpoint modulation and broadly neutralizing antibodies.

Executive Summary

Key findings from pooled CCR5 antagonist analysis and FireGate pipeline snapshot.

Figure 1: PRISMA Flow Diagram




Figure 1. PRISMA flow diagram of CCR5 antagonist trials included in FireGate pooled analysis.

Figure 1. PRISMA flow diagram of CCR5 antagonist trials included in FireGate pooled analysis.

Figure 2: Forest Plot




Figure 2. Forest plot of pooled effect sizes from CCR5 antagonist trials: (A) viral load reduction and (B) CD4+ T-cell increase.

Figure 2. Forest plot of pooled effect sizes from CCR5 antagonist trials: (A) viral load reduction and (B) CD4+ T-cell increase.

Pipeline

Program	Indication	Stage
FG-001	HIV Cure Protocol (CCR5 Blockade + PD-L1 Modulation + bNAbs)	Preclinical
FG-002	AI-Repurposed Immunotherapy (Triple-Negative Breast Cancer)	Discovery
FG-003	Neuro-Immune Modulation (Autoimmune/Neuroinflammatory)	Concept Development

Closing Vision

FireGate Biotech is engineering oversight-driven discovery where innovation is inseparable from accountability.

Appendix — Patient-Level Dataset

Study	n	Effect Size	95% CI	Weight
Study A	102	-1.70	-1.45 to -1.95	8.5%
Study B	250	-1.88	-1.60 to -2.10	15.2%
Study C	300	-1.90	-1.75 to -2.05	22.0%